The pervasive contamination of ecosystems with active pharmaceutical ingredients poses a serious threat to biodiversity, ecosystem services and public health. Urgent action is needed to design greener drugs that maintain efficacy but also minimize environmental impact.
This is a preview of subscription content, log in via an institution to check access.
References
Wilkinson, J. L. et al. Proc. Natl Acad. Sci. USA 119, e2113947119 (2022).
Bouzas-Monroy, A., Wilkinson, J. L., Melling, M. & Boxall, A. B. A. Environ. Toxicol. Chem. 41, 2008–2020 (2022).
Proposal for a Directive of the European Parliament and of the Council amending Directive 2000/60/EC establishing a framework for Community action in the field of water policy, Directive 2006/118/EC on the protection of groundwater against pollution and deterioration and Directive 2008/105/EC on environmental quality standards in the field of water policy (European Commission, 2022).
Persson, L. et al. Environ. Sci. Technol. 56, 1510–1521 (2022).
Kidd, K. A. et al. Proc. Natl Acad. Sci. USA 104, 8897–8901 (2007).
Saaristo, M. et al. Proc. R. Soc. B 285, 20181297 (2018).
Mehdi, H. et al. Sci. Total Environ. 759, 143430 (2021).
Communication from the Commission. European Union Strategic Approach to Pharmaceuticals in the Environment (European Commission, 2019).
Improving prescribing and medicines use: sustainable prescribing. Royal Pharmaceutical Society (2021); https://go.nature.com/3V4dk8j
Jones, E. R., Van Vliet, M. T. H., Qadir, M. & Bierkens, M. F. P. Earth Syst. Sci. Data 13, 237–254 (2021).
Bourgin, M. et al. Water Res. 129, 486–498 (2018).
Somasundar, Y. et al. ACS EST Water 1, 2155–2163 (2021).
Kümmerer, K. Green Chem. 9, 899–907 (2007).
Leder, C. et al. ACS Sustain. Chem. Eng. 9, 9358–9368 (2021).
Puhlmann, N., Mols, R., Olsson, O., Slootweg, J. C. & Kümmerer, K. Green Chem. 23, 5006–5023 (2021).
Acknowledgements
We acknowledge funding support from the Swedish Research Council Formas (2018-00828 to T.B., 2020-02293 to M.G.B., 2020-00981 to E.S.M., 2020-01052 to D.C., 2022-00503 to M.M. and 2022-02796/2023-01253 to J.M.M.), the Kempe Foundations (SMK-1954, SMK21-0069 and JCSMK23-0078 to M.G.B.), the Swedish Research Council VR (2022-03368 to E.S.M.), the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement (101061889 to M.M.), Research England (131911 to M.J.), the Spanish Ministry of Economy, Industry and Competitiveness (PID2022-139746OB-I00/AEI/10.13039/501100011033 to G.O.), the Australian Research Council (FT190100014 and DP220100245 to B.B.M.W.), the Jarislowsky Foundation (to K.A.K.), a Royal Society of New Zealand Catalyst Leaders Fellowship (ILF-CAW2201 to B.W.B.) and the National Institute of Environmental Health Sciences of the National Institutes of Health (1P01ES028942 to B.W.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Sustainability thanks Lydia Niemi, Terrence Collins and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Rights and permissions
About this article
Cite this article
Brodin, T., Bertram, M.G., Arnold, K.E. et al. The urgent need for designing greener drugs. Nat Sustain (2024). https://doi.org/10.1038/s41893-024-01374-y
Published:
DOI: https://doi.org/10.1038/s41893-024-01374-y
- Springer Nature Limited